JIMT-1 Xenograft Model Service for Breast Cancer

The JIMT-1 xenograft model delivers a powerful in vivo platform designed to evaluate candidate therapies targeting aggressive, HER2-positive breast cancers that possess intrinsic resistance to multiple current treatments. Alfa Cytology provides a comprehensive, end-to-end JIMT-1 xenograft model service, integrating fully authenticated cellular assets with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of JIMT-1 Xenograft Model for Breast Cancer

The JIMT-1 cell line is a highly valuable human mammary carcinoma model, clinically renowned for its intrinsic resistance to HER2-targeted therapies such as trastuzumab and various small-molecule inhibitors. Derived from a primary ductal carcinoma, this model exhibits high HER2 amplification and overexpression but remains insensitive to blockade, largely due to activating mutations in the PIK3CA gene (specifically the pathogenic E545K mutation), which hyperactivates downstream signaling pathways independent of HER2 engagement. JIMT-1 xenografts provide an essential in vivo translation platform to explore resistance mechanisms, evaluate novel combination therapies (including HER2/PI3K pathway inhibition), and test advanced anti-cancer agents like antibody-drug conjugates (ADCs) specifically designed to overcome targeted therapy insensitivity.

When established in vivo as a xenograft in immunodeficient mice, JIMT-1 cells form solid tumors that faithfully recapitulate the complex histopathological microenvironment and distinct molecular characteristics of treatment-resistant human breast malignancies. To ensure reliable growth, specialized inoculation techniques involving biological matrix supports are required.

Fig 1. Effect of HVH-2930 and paclitaxel (PTX) combination treatment on trastuzumab-resistant JIMT-1 xenografts. (Park M, et al., 2024)

Cell Line Information: JIMT-1

The JIMT-1 cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary HER2 amplification and PIK3CA-driven resistance signatures upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the JIMT-1 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the JIMT-1 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2 expression and PK/PD profiling. Leveraging our expertise in trastuzumab-resistant HER2-positive breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of JIMT-1 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the JIMT-1 xenograft model:

• Cell Culture & Quality Control: JIMT-1 cells are cultivated in specialized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice (e.g., Nude or SCID) are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of JIMT-1 cells is prepared and blended with a biological matrix carrier (e.g., Matrigel) to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. JIMT-1 Xenograft Model Construction Workflow

Case Study - JIMT-1 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the JIMT-1 xenograft model was successfully utilized to evaluate the efficacy of a novel antibody-drug conjugate candidate targeting refractory HER2-positive breast cancer. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Why Choose Alfa Cytology?

Choosing the right partner for your resistant HER2-positive breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling, to secure baseline stability.
• Technical Reproducibility: Optimized inoculation methodologies designed to achieve uniform tumor growth kinetics.
• Comprehensive Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking and PK/PD tissue processing.
• Scientific Integrity: All studies are executed by a specialized team providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against resistant, HER2-positive breast cancer using the robust JIMT-1 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.